Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types

BACKGROUND: Bullous pemphigoid (BP) is an autoimmune skin-blistering disease. Systemic corticosteroids remain the first line treatment for moderate-to-severe BP with the potential for severe adverse events. Dupilumab has emerged as an alternative option for BP patients. OBJECTIVE: We evaluated the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Tianmeng, Xie, Yinghan, Liu, Yuhua, Shan, Ying, Wu, Xiaoyan, Wang, Jing, Zuo, Ya-Gang, Zhang, Zhenying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421662/
https://www.ncbi.nlm.nih.gov/pubmed/37575240
http://dx.doi.org/10.3389/fimmu.2023.1194088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421662/
https://www.ncbi.nlm.nih.gov/pubmed/37575240
http://dx.doi.org/10.3389/fimmu.2023.1194088

Ejemplares similares